Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study
Sign Up to like & getrecommendations! Published in 2020 at "Investigational New Drugs"
DOI: 10.1007/s10637-020-00925-2
Abstract: Purpose Apatinib, a new tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, has shown promising efficacy against several solid cancers, but evidence of its efficacy against relapsed and refractory nasopharyngeal carcinoma is limited. We… read more here.
Keywords: relapsed refractory; kinase inhibitor; refractory nasopharyngeal; nasopharyngeal carcinoma ... See more keywords